File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801)

TitlePrognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801)
Authors
KeywordsCA125
Ovarian tumors of low malignant potential
Survival
Issue Date2012
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygyno
Citation
Gynecologic Oncology, 2012, v. 126 n. 1, p. 36-40 How to Cite?
AbstractObjective: Previous studies on prognostic factors in ovarian tumors of low malignant potential (LMP) were too small for robust conclusions. We examined the prognostic impact of preoperative serum CA125 ≥ 50 U/ml levels in patients diagnosed with ovarian LMP tumors in a large multinational cohort. Methods: This retrospective study included 940 patients with ovarian LMP tumors diagnosed between 1985 and 2008 at six gynecologic cancer centers. Patients either had radical treatment (bilateral salpingo-oophorectomy with or without hysterectomy) or conservative, fertility-sparing treatment. Multivariate Cox proportional hazard models were used to determine independent prognostic factors for disease-free (DFS) and overall survival (OS). Based on receiver operating characteristic curve (ROC), a preoperative serum CA125 level ≥ 50 U/ml was considered "elevated". Results: CA125 was more often elevated in serous than in mucinous tumors and in advanced FIGO stages (2 to 4) compared to stage1. DFS at 5 years was 89% and 95% in patients with elevated and normal CA125 levels (p < 0.05). Similarly, the 5-year OS was 90% among patients with elevated CA125 compared to 95% among patients with normal levels (p < 0.05). For both DFS and OS elevated CA125 levels and advanced stages of the disease were independent prognostic factors. Analysis of subgroups revealed that CA125 was only prognostic in serous LMP tumors. Conclusions: In the context of serous ovarian LMP tumors, elevated preoperative serum CA125 represents a biomarker independently associated with impaired disease-free and overall survival. CA125 is available in most centers and could inform surgeons about the risk of treatment failure. Crown Copyright © 2012 Published by Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/152942
ISSN
2015 Impact Factor: 4.198
2015 SCImago Journal Rankings: 2.284
ISI Accession Number ID
Funding AgencyGrant Number
Royal Brisbane
Women's Hospital Research Foundation, Brisbane, Australia
Funding Information:

This study was partly funded by the Royal Brisbane and Women's Hospital Research Foundation, Brisbane, Australia. The authors would like to thank all the participants from each center who have contributed to this study and especially to Ms. Karen Sanday for her effort in data management. We also would like to thank the ANZGOG Coordinating Centre at the NHMRC Clinical Trials Centre, University of Sydney, for assistance with the surveys. We would also like to thank the following specialists for their support with this study: Drs. James Nicklin, Lewis Perrin, Russell Land, Andrea Garrett, Marcelo Nascimento, Alex Crandon, Tony McCartney, Stuart Salfinger, Ian Hammond, Deborah Neesham, Robert Rome, Christopher Dalrymple, Kenneth Atkinson, Selvan Pather, Karfai Tan, Ty Ng, Ruud Bekkers, Leon Massuger and Joanne de Hullu.

References

 

DC FieldValueLanguage
dc.contributor.authorTang, Aen_HK
dc.contributor.authorKondalsamyChennakesavan, Sen_HK
dc.contributor.authorNgan, Hen_HK
dc.contributor.authorZusterzeel, Pen_HK
dc.contributor.authorQuinn, Men_HK
dc.contributor.authorCarter, Jen_HK
dc.contributor.authorLeung, Yen_HK
dc.contributor.authorObermair, Aen_HK
dc.date.accessioned2012-07-16T09:52:54Z-
dc.date.available2012-07-16T09:52:54Z-
dc.date.issued2012en_HK
dc.identifier.citationGynecologic Oncology, 2012, v. 126 n. 1, p. 36-40en_HK
dc.identifier.issn0090-8258en_HK
dc.identifier.urihttp://hdl.handle.net/10722/152942-
dc.description.abstractObjective: Previous studies on prognostic factors in ovarian tumors of low malignant potential (LMP) were too small for robust conclusions. We examined the prognostic impact of preoperative serum CA125 ≥ 50 U/ml levels in patients diagnosed with ovarian LMP tumors in a large multinational cohort. Methods: This retrospective study included 940 patients with ovarian LMP tumors diagnosed between 1985 and 2008 at six gynecologic cancer centers. Patients either had radical treatment (bilateral salpingo-oophorectomy with or without hysterectomy) or conservative, fertility-sparing treatment. Multivariate Cox proportional hazard models were used to determine independent prognostic factors for disease-free (DFS) and overall survival (OS). Based on receiver operating characteristic curve (ROC), a preoperative serum CA125 level ≥ 50 U/ml was considered "elevated". Results: CA125 was more often elevated in serous than in mucinous tumors and in advanced FIGO stages (2 to 4) compared to stage1. DFS at 5 years was 89% and 95% in patients with elevated and normal CA125 levels (p < 0.05). Similarly, the 5-year OS was 90% among patients with elevated CA125 compared to 95% among patients with normal levels (p < 0.05). For both DFS and OS elevated CA125 levels and advanced stages of the disease were independent prognostic factors. Analysis of subgroups revealed that CA125 was only prognostic in serous LMP tumors. Conclusions: In the context of serous ovarian LMP tumors, elevated preoperative serum CA125 represents a biomarker independently associated with impaired disease-free and overall survival. CA125 is available in most centers and could inform surgeons about the risk of treatment failure. Crown Copyright © 2012 Published by Elsevier Inc. All rights reserved.en_HK
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygynoen_HK
dc.relation.ispartofGynecologic Oncologyen_HK
dc.subjectCA125en_HK
dc.subjectOvarian tumors of low malignant potentialen_HK
dc.subjectSurvivalen_HK
dc.titlePrognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801)en_HK
dc.typeArticleen_HK
dc.identifier.emailNgan, H:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, H=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ygyno.2012.02.031en_HK
dc.identifier.pmid22370601-
dc.identifier.scopuseid_2-s2.0-84862768379en_HK
dc.identifier.hkuros201374en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84862768379&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume126en_HK
dc.identifier.issue1en_HK
dc.identifier.spage36en_HK
dc.identifier.epage40en_HK
dc.identifier.isiWOS:000305878400008-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTang, A=26655116300en_HK
dc.identifier.scopusauthoridKondalsamyChennakesavan, S=8868800300en_HK
dc.identifier.scopusauthoridNgan, H=34571944100en_HK
dc.identifier.scopusauthoridZusterzeel, P=6602733885en_HK
dc.identifier.scopusauthoridQuinn, M=7202672447en_HK
dc.identifier.scopusauthoridCarter, J=35354020600en_HK
dc.identifier.scopusauthoridLeung, Y=7201463926en_HK
dc.identifier.scopusauthoridObermair, A=7006307099en_HK
dc.identifier.citeulike10420706-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats